Search

Displaying results 1651 - 1660 of 5900 in total
  1. Drug

    Beeswax

    go.drugbank.com/drugs/DB11600
    Approved

    Beeswax is used as a stiffening agent in ointments and creams, and enables water to be incorporated to produce water-in-oil emulsions.

  2. Drug

    gamma-Butyrolactone

    go.drugbank.com/drugs/DB04699
    ExperimentalIllicit

    One of the furans with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate.

    Synonyms: dihydrofuran-2(3h)-one
  3. Drug

    Polysilicone-15

    go.drugbank.com/drugs/DB11271
    Approved

    It is the first polymeric UVB filer consisting of chromophores attached to a silicone backbone [L2796, L2797, L2799, F87, F88, F89]. … The compound is a colorless to pale yellow viscous liquid which is soluble in organic solvents of medium polarity and insoluble in water [L2796, L2797, L2799, F87, F88, F89].

  4. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

    Synonyms: 4-(2-(tert-butylamino)-1-hydroxyethyl)-o-phenylene di-p-toluate, 4-[2-(tert-butylamino)-1-hydroxyethyl]-o-phenylene di-p-toluate
  5. Drug

    Carindacillin

    go.drugbank.com/drugs/DB09319
    ApprovedWithdrawn

    It is no longer marketed in the United States.

  6. Drug

    Oxybutynin

    go.drugbank.com/drugs/DB01062
    ApprovedInvestigational

    Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.

    Products: OSSIBUTININA CLORIDRATO MYLAN GENERICS
  7. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339] … [L51329] CLN2 is a predominantly pediatric-onset neurodegenerative disease caused by a deficiency in the lysosomal enzyme TPP1, leading to progressive impairment in motor and cognitive function.

  8. Drug

    Antihemophilic factor human

    go.drugbank.com/drugs/DB13192
    ApprovedInvestigational

    Endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as a co-factor to Factor IX. … Activation of Factor IX leads to a cascade of signals that results in activation of Factor X, which then results in the conversion of prothrombin to thrombin, and as a result, leads to the conversion of

  9. Drug

    Deferoxamine

    go.drugbank.com/drugs/DB00746
    ApprovedInvestigational

    Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

  10. Drug

    Tinzaparin

    go.drugbank.com/drugs/DB06822
    ApprovedInvestigational

    LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa.